Please assess the completion status of the following clinical trial:

Trial Title: A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have had a diagnosis of type 2 diabetes mellitus~* Participants who have been treated with insulin therapy (basal insulin, premixed insulin, or basal/mealtime insulin regimen) with or without 1 or 2 oral antidiabetics (OADs) at stable dose for at least 3 months before screening~* Participants who have an HbA1c value ≥7.0% and ≤10.5% at screening if the participant is washing out OADs (dipeptidyl peptidase-4 \[DPP-4\] inhibitors, sulfonylurea \[SU\], or glinides) or ≥7.5% and ≤10.5% at screening if the participant is not washing out OADs~* Participants who have stable weight (±5%) ≥3 months prior to screening~* Participants who have a body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m\^2)~Exclusion Criteria:~* Participants who have a diagnosis of type 1 diabetes~* Participants who have previously received therapy with a glucagon-like peptide-1 receptor agonist within 3 months prior to screening~* Participants who have been previously treated with dulaglutide prior to screening~* Participants who have been treated with 2 of the following at screening: DPP-4 inhibitor, SU, and glinide (ie, DPP-4 inhibitor and SU, or DPP-4 inhibitor and glinide)~* Participants who have been treated with continuous subcutaneous insulin infusion (CSII) at screening~* Participants who have clinically significant gastric emptying abnormality, hepatitis, pancreatitis, renal dysfunction, or thyroid abnormalities~* Participants who have a history of clinically significant cardiovascular disease, transplanted organ, or active or untreated malignancy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dulaglutide (Type: EXPERIMENTAL): Dulaglutide 0.75 milligram (mg) administered once weekly for 16 weeks. After 16-weeks, dulaglutide administered once weekly for 36 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered once weekly for 16 weeks. After 16-weeks, dulaglutide 0.75 mg administered once weekly for 36 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).